Emisión de equidad y derechos de voto total
22 de abril de 2024
Grupo Avacta plc
("Avacta" o el "Grupo" o la "Compañía")
Emisión de equidad y derechos de voto total
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics today announces it has issued and allotted a total of 7,529,825 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued in settlement of the quarterly principal of £2.55 million and interest repayment of £0.62 million in respect of the Company's unsecured convertible bonds (the "Convertible Bonds"), as detailed in Avacta's announcement on 18 October 2022.
The Board carefully considered the difficult balance between further dilution and the Group's cash resources to deliver key value adding milestones from the upcoming AVA6000 efficacy studies. On this occasion the Board has decided to settle the quarterly repayment in shares but will continue to review this on a quarterly basis and, if it considers that conditions allow, the repayment will be settled in cash.
After settlement of the quarterly repayment, the principal remaining under the Convertible Bonds will be reduced by £2.55 million to £35.70 million.
Under the terms and conditions of the Convertible Bonds, there is a reset of the conversion price on the date falling 18 months after their date of issue (i.e. on 20 April 2024, the "Reset Date") should the average Avacta share price over the 15-dealing-day period preceding the Reset Date(1) (the "15-Day Reset Average Market Price") be below the conversion price in effect on the Reset Date(2). In which case, the conversion price resets to the greater of (i) such 15-Day Reset Average Market Price and (ii) the reset price floor in effect on the Reset Date(3). The 15-Day Reset Average Market Price is 50.83 pence and, as such, with effect from the Reset Date of 20 April 2024, the conversion price was reset to 88.72 pence(4), subject as provided below.
If, during the 9-month period commencing on the Reset Date (i.e. during the period from 20 April 2024 to 20 January 2025, the "Reset Clawback Period"), the volume-weighted average price ("VWAP") of the Company's Ordinary Shares on each of at least 20 dealing days in any period of 30 consecutive dealing days is greater than 130% of the pre-reset conversion price(5) (the "Reference Conversion Price"), then the conversion price will be restored at such time to be equal to such Reference Conversion Price(5), thereby reversing the effect of the reset made on 20 April 2024.
Se ha presentado una solicitud a AIM para la admisión a cotización de las 7,529,825 Nuevas Acciones Ordinarias resultantes de la conversión, que se espera que ocurra alrededor de las 8.00:23 am del 2024 de abril de XNUMX ("Admisión"). Las Nuevas Acciones Ordinarias tendrán rango pari passu con las Acciones Ordinarias existentes de la Compañía.
Tras la Admisión, el capital social ampliado emitido de la Sociedad será de 359,042,104. Esta cifra podrá ser utilizada por los accionistas de la Sociedad como denominador para los cálculos mediante los cuales determinarán si están obligados a notificar su participación o un cambio en su participación en el capital social de la Sociedad de conformidad con la Autoridad de Conducta Financiera. Guía de Divulgación y Reglas de Transparencia.
(1) being calculated as the arithmetic average of the daily VWAPs of the Ordinary Shares during such 15-dealing-day period as aforesaid
(2) being 110.91 pence since the adjustment performed in accordance with the customary anti-dilution provisions contained in the terms and conditions of the Convertible Bonds following the Company's fundraise announced on 28 February 2024 (the conversion price was initially set at 118.75 pence at the time of issue of the Convertible Bonds)
(3) being 88.72 pence since the adjustment referred to in note (1) above (the reset price floor was initially set at 95 pence at the time of issue of the Convertible Bonds)
(4) from 110.91 pence immediately prior to the Reset Date
(5) being 110.91 pence, as may be adjusted during the Reset Clawback Period in accordance with the customary anti-dilution provisions contained in the terms and conditions of the Convertible Bonds
-Termina
Para obtener más información de Avacta Group plc, comuníquese con:
Grupo Avacta plc Alastair Smith, director ejecutivo Tony Gardiner, director financiero Michael Vinegrad, director de comunicaciones del grupo
| Tel: + 44 (0) 1904 21 7070 www.avacta.com |
Stifel Nicolaus Europa limitada (Nómada y Sociedad Conjunta Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good
| Tel: + 44 (0) 207 710 7600 www.stifel.es |
Peel Hunt (empresa conjunta Broker) James Steel / Chris Golden / Patrick Birkholm | Tel: + 44 (0) 207 418 8900 www.peelhunt.com
|
Consilium ICR (Medios e IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
Acerca de Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta has two divisions focused on therapeutics and diagnostics.
Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.
Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.
Avacta has two proprietary platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.
Para registrarse para recibir alertas de noticias por correo electrónico, vaya a https://avacta.com/investors/investor-news-email-alerts/
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.